We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings. OK Contact News via mail Medicine Safety Galapagos around the world In the spotlight Q3 results 2021 Read the press release Discover the full report Replay the webcast We are Galapagos Galapagos discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in clinical development in multiple diseases. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and available to patients in Europe, Great Britain and Japan (under a collaboration with Gilead) for rheumatoid arthritis. Learn more about Galapagos News November 22, 2021 Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease November 15, 2021 Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis November 04, 2021 Galapagos reports commercial and operational progress at Q3 financial results All Galapagos news Events January 13, 2022 J.P. Morgan February 14, 2022 SVB Leerink Virtual 11th Annual Global Healthcare Conference Virtual All Galapagos events Job Openings International Marketing Manager Inflammation - remote position Commercial Talent & Development Lead - Mechelen, BE / Leiden, NL Shared Services - HR Scientist Target Modulation, Specialist in Biophysics– Mechelen,BE Research - In Vitro Biology All Current Openings It is all about innovation Watch our CEO explain the 10-year partnership with Gilead. © Copyright 2021 Galapagos NV ● Disclaimer ● Privacy notice ● Cookie policy ● Terms ● News via mail ● Community guidelines